Author

Manuela Iezzi

University of Chieti-PescaraORCID 0000-0002-6296-6498Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:statistical model· 1

Frequent Co-Authors

Alessia LamolinaraiD· 2 shared Alessandro SarcinellaiD· 1 shared Andrea Scavuzzo· 1 shared Barbara BellettiiD· 1 shared Carla Mottini· 1 shared Daniela TavernaiD· 1 shared Daniela TosoniiD· 1 shared Elisa Cacciagrano· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alessia LamolinaraORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

p140Cap enhances breast cancer chemosensitivity by limiting an ABCC1-enriched stem-like compartment via β-Catenin inhibition

Andrea Scavuzzo, Matteo Poncina, Alessia Lamolinara, Alessandro Sarcinella, Mahdis Jahanbin, Maria Grazia Filippone, Laura Bottoni, Francesco Antonio Tucci, Yaron Vinik, Sima Lev, Manuela Iezzi, Ugo Ala, Daniela Taverna, Francesca Orso, Barbara Belletti, , Vincenzo Salemme

This study shows p140Cap improves chemotherapy response in breast cancer by reducing stem-like cells and enhancing drug retention through β-Catenin inhibition.

bioRxiv · Aug 18, 2026 · PreprintCancer Biology

Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent Tumors

Giorgia Anastasio, Michela Felaco, Alessia Lamolinara, Francesco del Pizzo, Elisa Cacciagrano, Carla Mottini, Margherita Mutarelli, Francesca Di Modugno, Manuela Iezzi, Luca Cardone

This paper shows that low-dose decitabine combined with olaparib enhances antitumor activity in KRAS-dependent pancreatic ductal adenocarcinoma, regardless of BRCA1/2 status.

iScience · Jan 20, 2025Peer-reviewedCancer Biology